Prkab1 Mouse shRNA Plasmid (Locus ID 19079)
CAT#: TL501734
Prkab1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (3)
Specifications
Product Data | |
Product Name | Prkab1 Mouse shRNA Plasmid (Locus ID 19079) |
Locus ID | 19079 |
UniProt ID | Q9R078 |
Synonyms | 1300015D22Rik; AU021155; E430008F22 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | Prkab1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 19079). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | BC016398, NM_031869, NM_031869.1, NM_031869.2, BC027650 |
Summary | Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3) (By similarity).[UniProtKB/Swiss-Prot Function] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
AMP kinase promotes glioblastoma bioenergetics and tumour growth
,Chhipa, RR;Fan, Q;Anderson, J;Muraleedharan, R;Huang, Y;Ciraolo, G;Chen, X;Waclaw, R;Chow, LM;Khuchua, Z;Kofron, M;Weirauch, MT;Kendler, A;McPherson, C;Ratner, N;Nakano, I;Dasgupta, N;Komurov, K;Dasgupta, B;,
Nat. Cell Biol.
,PubMed ID 29915361
[PRKAB1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...